07.02.2013 - US biotech Biogen Idec has bagged full rights to Elan's Multiple Sclerosis blockbuster Tysabri in a US$3.25bn deal.
The news came following rumours that Biogen Idec plans to take over the Irish drugmaker, after its Alzheimer antibody bapineuzumab failed in a Phase III study. Biogen instead decided to take full ownership of the currently most effective therapy for the relapsing form of multiple sclerosis (MS) for US$3.25bn. Under the terms of the agreement, Elan will receive 12% of global net sales for the first year after the deal is completed. After that, Elan will receive 18% on up to US$2bn of global net sales and 25% on any sales over that amount. Last year Tysabri made US$1.6bn (+8%) but an MAA as first line treatment filed last month is expected to further boost sales. "The restructuring of this business collaboration provides Elan with significant strategic flexibility," said the company's CEO Kelly Martin.
With the deal, Biogen Idec strengthens its MS drug portfolio after having co-marketed the antibody Tysabri with Elan since 2004. The US company filed for US approval of its oral dimethyl-fumarate BG-12 (Tecfidera) last year. Biogen could then offer the Interferon beta-1a Avonex alongside with BG-12 and Tysabri strenghtening the company's position in the lucrative MS market against Novartis, Teva, Merck KGaA and Bayer.
28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.